The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatment

If you’ve been around cancer headlines long enough, you’ve seen the movie trailer: “Simple chemical. Old drug.
Big promise. Big resistance. Big pharma villain monologue.” And then, like a plot twist you can set your watch to,
the actual data strolls in wearing sensible shoes and says, “So… about that.”

Dichloroacetateusually shortened to DCAhas lived this storyline for nearly two decades. It’s a small molecule,
long out of patent, with a plausible biological mechanism tied to cancer metabolism. That combination makes it catnip for
internet optimism and a recurring character in debates about how medical evidence is made, funded, and sometimes
wildly misinterpreted. The Science-Based Medicine take is basically: fascinating science, messy translation, and a lot of
people skipping to the “miracle cure” ending without reading the middle chapters.

What is DCA, and why did cancer researchers care?

DCA has been studied for years in metabolic and mitochondrial disorders because it can influence how cells process fuel.
In simplified terms: many cancer cells lean heavily on a metabolic pattern often discussed as the “Warburg effect,” where
cells burn through glucose in ways that favor rapid growth and survival strategies. That doesn’t mean cancer cells “don’t use oxygen”
(they often do). It means their metabolism can be rewired in ways that support tumor behavior.

DCA’s claim to fame is that it can inhibit pyruvate dehydrogenase kinase (PDK), which in turn can help activate
the pyruvate dehydrogenase complex (PDH)a key gateway that pushes pyruvate toward mitochondrial oxidation rather than
detouring into lactate production. On paper, that could make some cancer cells less comfortable, more stressed, and potentially
more vulnerable to cell death pathways.

This is the part where a responsible scientist says, “Interesting hypothesisnow we test it.” This is also the part where the internet says,
“We have already printed the t-shirts.”

The 2007–2010 hype wave: a mechanism meets a megaphone

Around the late 2000s, early laboratory and animal work helped propel DCA into the public spotlight. The story had everything:
metabolism! mitochondria! a cheap compound! and the irresistible suggestion that cancer could be tackled by “flipping the switch”
on how cells make energy. Science-Based Medicine chronicled how unusual it was to see the normal step-by-step pipelinecell studies,
animal work, carefully designed human trialsget pressured in public by a wave of patient-driven urgency and media amplification.

And look, the urgency is real. Cancer is not a polite disease that waits for grant cycles. But urgency doesn’t turn preliminary evidence into
clinical proof. It just raises the stakes if we get it wrong.

Why “it shrank tumors” isn’t the same as “it helped people live longer”

One reason DCA arguments keep looping is that cancer research is full of measurements that are easy to celebrate but hard to interpret.
Tumor shrinkage, biomarker changes, and imaging-based signals can matterbut they’re often surrogate endpoints, not the
outcomes people actually care about (living longer, feeling better, avoiding disability, etc.).

Surrogates can be useful for early learning, but they can also mislead. A therapy can nudge a marker without improving survival,
or it can even improve a short-term measure while causing harms that offset any benefit. The point isn’t that surrogates are “fake.”
It’s that they’re provisional. They’re a clue, not a verdict.

What human evidence exists for DCA in cancer?

DCA has been tested in limited clinical contexts, particularly in difficult-to-treat cancers like malignant brain tumors.
The best way to describe the human evidence so far is: feasibility and safety questions have been explored more than clear efficacy.
That’s not an insult; it’s how early clinical research works. Before you can prove benefit, you need to know dosing, tolerability,
interactions, and the “what could go wrong?” list.

Brain tumor studies: signals of feasibility, not a clean win

A notable Phase 1 study in adults with recurrent malignant brain tumors reported that chronic oral DCA was feasible and generally tolerated
within certain dose ranges, with emphasis on using genetic information (involving GSTZ1/MAAI variation) to guide dosing and reduce risk.
The study was not designed to prove DCA “works” as an anti-cancer treatment; Phase 1 trials typically aren’t. They’re more like:
“Can humans take this safely enough to justify bigger studies?”

That “genetic-based dosing” detail is not a footnote. DCA metabolism is influenced by enzymes that vary across people,
and that means two patients taking “the same dose” can experience very different exposures and side effect risks.
This is one reason DIY DCA useespecially sourced from sketchy sellersshould set off alarm bells.

Ongoing and recent trial activity

Trials have continued to appear and reappear over the years, including work in glioblastoma (GBM), one of the most aggressive brain cancers.
For example, an NCI-listed Phase IIA trial design has looked at short-term oral DCA exposure in surgical patients with recurrent GBM,
incorporating genotyping and biochemical markers to better understand how the drug behaves in real tumor tissue.
That’s a very “science-based” kind of next step: not promising miracles, but improving the map before charging into a bigger expedition.

The safety reality check: DCA is not vitamin-flavored

DCA’s safety profile is one of the most important reasons the saga hasn’t ended with a triumphant FDA approval for oncology.
The headline concern that repeatedly shows up is peripheral neuropathydamage to peripheral nerves that can cause numbness,
tingling, pain, weakness, and functional impairment. Sometimes it improves after stopping the drug; sometimes nerve issues can linger.

A randomized controlled trial in a mitochondrial disease context (MELAS) reported toxic neuropathy associated with DCA.
That trial wasn’t even in cancer patients; it was in a setting where DCA’s metabolic effects were being explored for a different reason.
The takeaway is simple: DCA can have clinically meaningful nerve toxicity, and you don’t get to hand-wave that away with
“but it’s cheap” or “but it’s natural” (it’s not natural; it’s chemistry).

If DCA is cheap, why hasn’t it been fully tested and approved for cancer?

The cynical answer is: “Because conspiracies.” The grown-up answer is: “Because the incentives and evidence thresholds are complicated.”

1) The funding problem is real, but it doesn’t prove efficacy

Off-patent compounds are harder to monetize, which can reduce private investment in large, expensive trials. That can slow progress.
But “hard to fund” is not the same thing as “it works and they’re hiding it.” Many plausible, inexpensive therapies fail in later-stage trials
because biology is ruthless and tumors are adaptable.

2) Cancer metabolism isn’t a single light switch

Even if DCA meaningfully shifts metabolism in some cells, tumors can be heterogeneous. The microenvironment matters.
Genetic drivers matter. The immune system matters. Standard therapies matter. Cancer cells can reroute pathways like a city with infinite side streets.
Metabolic therapy is a real research frontier, but it rarely behaves like a universal master key.

3) Dose-limiting toxicity can cap the “theory dose”

You can often blast cancer cells in a dish with concentrations that would be unsafe in humans. Real-world dosing is a negotiation:
enough exposure to plausibly help, not so much that patients trade cancer for debilitating side effects.

The plot twist of 2025: DCA’s “other life” in rare disease regulation

While DCA’s cancer story remains unsettled, it has also been developed in the rare disease arena. In 2025, Saol Therapeutics received an FDA
Complete Response Letter regarding its application for a sodium dichloroacetate oral solution (SL1009) for
pyruvate dehydrogenase complex deficiency (PDCD). A CRL means the FDA is not approving the application in its current form
and is requesting additional workoften including more clinical datato address remaining questions.

This matters for two reasons. First, it underscores that DCA isn’t some forbidden molecule that “they won’t let anyone study.”
It is studied, and it is being pushed through formal regulatory channels for specific indications. Second, it highlights the difference between
“interest in a drug” and “proof of benefit.” Even in urgent rare diseases, the bar still includes evidence and safety clarity.

So where does that leave DCA as a cancer treatment?

DCA sits in a frustrating middle space: too biologically plausible to ignore, too clinically unproven (and potentially toxic) to crown.
The science-based position is not “never.” It’s “not yetand not by vibes.”

The most responsible future for DCA in oncology would look like:

• Better patient selection (who is most likely to respond based on tumor biology and metabolism?)
• Careful dosing strategies that account for genetic variability in metabolism
• Combination logic (if DCA helps at all, is it as an add-on to standard therapy, not a replacement?)
• Endpoints that matter (survival, quality of life, functionnot just a prettier scan)
• Transparent reporting so hype doesn’t outrun the facts

What patients should know (without turning this into a lecture)

If you or someone you love is dealing with cancer, the appeal of DCA is understandable: it sounds scientific, it’s not new,
and the internet is full of “why isn’t anyone talking about this?” posts. But here’s the grounded reality:
outside properly monitored clinical trials (or tightly supervised medical settings), using DCA as a cancer treatment can expose patients to
nerve toxicity and other risks without clear evidence of benefit.

If you see DCA marketed online as a cureor bundled into a “secret protocol”treat that like a smoke alarm, not a shopping suggestion.
Real breakthroughs welcome scrutiny. They don’t need to hide behind urgency, secrecy, or conspiratorial storytelling.

Experiences from the real world: what the DCA saga feels like on the ground (extra )

The DCA story isn’t just a debate about enzymes and endpoints. It’s also a human experienceoften a stressful onebecause it tends to surface
when people are scared, searching, and exhausted from hearing “limited options.” In online forums and patient communities,
DCA frequently appears in the same breath as phrases like “repurposed drug,” “metabolic therapy,” and “why isn’t this standard?”
You can almost see the emotional math happening: if the mechanism sounds logical and the molecule is cheap, then trying it feels like
taking control back from chaos.

Clinicians and researchers describe a different emotional landscape: the slow, unglamorous grind of translating a promising idea into an actual,
reproducible therapy. In that world, “promising” means “worth studying,” not “ready to recommend.” They’ve seen too many treatments
that looked brilliant in early models and then fizzled when tested against real tumors in real bodies. They’ve also seen the harm caused
when patients abandon proven therapies for something that’s trending. The DCA conversation often becomes a delicate balancing act:
respect the patient’s agency and urgency while also being honest about what the evidence doesand doesn’tsupport.

Then there are the practical experiences people report when DCA is used outside trials. One recurring theme is that side effects are not theoretical.
Numbness and tingling can creep in, and suddenly the “it can’t hurt to try” mindset collides with the reality that nerves are not easily replaced.
Some individuals describe stopping and starting, adjusting doses, or stacking supplements in an attempt to manage symptomsoften without
consistent medical oversight. That’s not a moral failing; it’s what happens when hope meets an unregulated marketplace.
But it does illustrate why formal trials exist: to replace improvisation with knowledge.

Another “experience layer” is the whiplash of headlines. Every few years, a new paper, a new case report, or a new clinic marketing push
makes it feel like the story is “back.” People share links, ask for protocols, and wonder if this is finally the breakthrough chapter.
Meanwhile, the scientific process keeps asking its unromantic questions: What’s the dose? Who benefits? What harms appear?
What endpoint matters? Has it been replicated? The mismatch in paceviral sharing versus clinical verificationcreates frustration.
Patients can feel dismissed; researchers can feel misquoted; families can feel stuck between “don’t give false hope” and “don’t take away hope.”

If there’s a lesson in these lived experiences, it’s that the need is real even when the answer isn’t ready. DCA became a symbol:
of drug repurposing potential, of distrust in incentives, and of the hunger for treatments that are both effective and accessible.
The most constructive version of that energy isn’t buying mystery powder online. It’s supporting well-designed research,
asking better questions, and demanding claritybecause if DCA ever does earn a place in cancer care, it will be because rigorous trials
proved it belongs there, not because the saga got enough retweets.

Conclusion

DCA remains one of the most instructive “almost-famous” compounds in modern cancer chatter: a biologically plausible idea that demonstrates
how easily hype can outrun evidence. Science-based medicine doesn’t require cynicism; it requires patience, good trials, and endpoints that matter.
The next chapter should be written by data, not desperationand definitely not by an online checkout page.